Funding

The "New Method" is currently developing criteria for which methods other than drugs shall be prioritized for assessment within the framework at the national or local levels. On January 17, 2022, the project status was presented at the Ordering Forum for "New Method." It was reported that the project would require more resources and time than initially thought.

On December 16, 2021, the Federal Joint Committee (G-BA) announced the start of the procedure concerning a co-funded study in accordance with §137e of the Social Code Book V (SGB V) for a low-intensity pulsed ultrasound for the treatment of pseudarthroses.

In December 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) finished the theme survey in the obstructive pulmonary diseases field, which was conducted as a part of the Orderly Introduction for Medical Technologies framework. Identified technologies could potentially be included in the Orderly Introduction of Medical Technologies framework, which aims to facilitate the introduction of novel technologies on the national level.

On November 18, 2021, Swedish Medical Technologies Product (MTP) Council recommended the use of gene expression analysis (Prosigna and OncotypeDX) for decision-making on the adjuvant breast cancer treatment. The technologies have been under evaluation within the Orderly introduction framework since 2020.

In November 2021, NHSX announced projects to improve digital pathways awarded for funding from the newly created Adoption Fund. Funding opportunities will support Integrated Care Systems (ICSs) with initiatives to test out digital pathways across various specialty areas, including gastroenterology, musculoskeletal, and cardiology. A total of 35 applications were successful and will share funding of £6.5 million.

On September 27, 2021, the Decision Forum for "New Methods" decided not to introduce bronchial thermoplasty as a routine treatment of patients with severe asthma. The method should only be used within clinical trials.

On September 29, 2021, NHSX announced the first phase winners of a Digital Health Partnership Award aimed to help NHS organizations receive funding to accelerate the adoption of digital health products and services to monitor patients with long-term conditions remotely. There will be three categories of funding: projects requiring the support of up to £100,000, £250,000, and £500,000.

On September 30, 2021, the 2020/21 National Tariff Payment System was published in England, and it came into effect on October 01, 2021. The publication has been delayed due to the COVID-19 pandemic.

On September 10, 2021, it was announced that the Government of Spain had increased the budget allocated to the Spanish Network of Agencies for the Evaluation of Health Technologies and Benefits (RedETS) by 48.2% (compared to last year) for the development of the annual work plan. In total, the 2021 budget for the evaluation of health technologies in the National Health System amounts to €6,149,510. As a consequence of the budget increase, the RedETS 2021 Work Plan has included three new lines of evaluation.

In August 2021, NHS announced rolling out genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia. These decisions are made in line with the NHS Long Term Plan committed to increasing access to genomic testing, improving diabetes care across the country, and investing in cutting-edge technologies.

On August 30, 2021, the Decision Forum for "New Methods" made a positive coverage decision for two methods: Transurethral Microwave Thermotherapy (TUMT) for benign prostatic hyperplasia treatment and organ donation using normothermic regional perfusion in patients with severe brain injury and who died of cardiac and respiratory arrest when life-prolonging treatment is discontinued.

On August 31, 2021, NHSX published a set of guidelines for digitized healthcare, including the Unified Tech Fund (UTF) prospectus, which seeks to simplify and consolidate the process for accessing technology funding. The UTF brings together several national technology funds. This amounts to £680 million available to NHS organizations throughout the financial year 2021 to 2022. The applications submission is open from August 31, 2021.